Pharmaceutical

Neurona raises $102m to advance cell therapy for drug-resistant epilepsy

Neurona will kick start a Phase III trial in H2 2025 investigating NRTX-1001 in patients with a type of drug-resistant epilepsy.

Apr 4, 2025 - 06:00
Neurona raises $102m to advance cell therapy for drug-resistant epilepsy
Neurona will kick start a Phase III trial in H2 2025 investigating NRTX-1001 in patients with a type of drug-resistant epilepsy.
Read the original article

Tags:

Previous Article

FDA awards ODD status to Sanofi’s rilzabrutinib for two rare conditions

Next Article

IO360 Summit: Improving CAR-T cell therapy manufacture and accessibility

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Reeves’ 2024 budget promises life sciences investment

Reeves’ 2024 budget promises life sciences investment

Nov 1, 2024

STAT+: Biotech FogPharma raises $145 million in anticipation of more clinical trials, pharma partnerships

STAT+: Biotech FogPharma raises $145 million in anticip...

Mar 2, 2024

Seres Therapeutics gets grant for composition of isolat...

Apr 25, 2024